Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses

DSpace/Manakin Repository

Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses

Citable link to this page

 

 
Title: Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses
Author: Trompet, Stella; de Craen, Anton JM; Postmus, Iris; Ford, Ian; Sattar, Naveed; Caslake, Muriel; Stott, David J; Buckley, Brendan M; Sacks, Frank Martin; Devlin, James J; Slagboom, P Eline; Westendorp, Rudi GJ; Jukema, J Wouter

Note: Order does not necessarily reflect citation order of authors.

Citation: Trompet, Stella, Anton JM de Craen, Iris Postmus, Ian Ford, Naveed Sattar, Muriel Caslake, et al. 2011. “Replication of LDL GWAs Hits in PROSPER/PHASE as Validation for Future (pharmaco)genetic Analyses.” BMC Medical Genetics 12 (1) (October 6). doi:10.1186/1471-2350-12-131.
Full Text & Related Files:
Abstract: BACKGROUND: The PHArmacogenetic study of Statins in the Elderly at risk (PHASE) is a genome wide association study in the PROspective Study of Pravastatin in the Elderly at risk for vascular disease (PROSPER) that investigates the genetic variation responsible for the individual variation in drug response to pravastatin. Statins lower LDL-cholesterol in general by 30%, however not in all subjects. Moreover, clinical response is highly variable and adverse effects occur in a minority of patients. In this report we first describe the rationale of the PROSPER/PHASE project and second show that the PROSPER/PHASE study can be used to study pharmacogenetics in the elderly. METHODS: The genome wide association study (GWAS) was conducted using the Illumina 660K-Quad beadchips following manufacturer's instructions. After a stringent quality control 557,192 SNPs in 5,244 subjects were available for analysis. To maximize the availability of genetic data and coverage of the genome, imputation up to 2.5 million autosomal CEPH HapMap SNPs was performed with MACH imputation software. The GWAS for LDL-cholesterol is assessed with an additive linear regression model in PROBABEL software, adjusted for age, sex, and country of origin to account for population stratification.
RESULTS: Forty-two SNPs reached the GWAS significant threshold of p = 5.0e-08 in 5 genomic loci (APOE/APOC1; LDLR; FADS2/FEN1; HMGCR; PSRC1/CELSR5). The top SNP (rs445925, chromosome 19) with a p-value of p = 2.8e-30 is located within the APOC1 gene and near the APOE gene. The second top SNP (rs6511720, chromosome 19) with a p-value of p = 5.22e-15 is located within the LDLR gene. All 5 genomic loci were previously associated with LDL-cholesterol levels, no novel loci were identified. Replication in WOSCOPS and CARE confirmed our results. CONCLUSION: With the GWAS in the PROSPER/PHASE study we confirm the previously found genetic associations with LDL-cholesterol levels. With this proof-of-principle study we show that the PROSPER/PHASE study can be used to investigate genetic associations in a similar way to population based studies. The next step of the PROSPER/PHASE study is to identify the genetic variation responsible for the variation in LDL-cholesterol lowering in response to statin treatment in collaboration with other large trials.
Published Version: doi:10.1186/1471-2350-12-131
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:30204032
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters